OncoMatch/Clinical Trials/NCT06988475
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
Is NCT06988475 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies Capmatinib for solid tumour.
Treatment: Capmatinib — This clinical trial is looking at a drug called capmatinib. Capmatinib is approved as standard of care treatment for adult patients with certain types of lung cancer. This means it has gone through clinical trials and been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. Capmatinib works in patients with lung cancer with a particular mutation in their cancer known as a METex14 skipping mutation. Investigators now wish to find out if it will be useful in treating patients with other cancer types which have the same mutation or other specific mutations or changes which take place in the MET gene. If the results are positive, the study team will work with the NHS and the Cancer Drugs Fund to see if these drugs can be routinely accessed for patients in the future. This trial is part of a trial programme called DETERMINE. The programme will also look at other anti-cancer drugs in the same way, through matching the drug to rare cancer types or ones with specific mutations.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Tumor Agnostic
Glioblastoma
Neuroblastoma
Gastric Cancer
Sarcoma
Biomarker criteria
Required: MET exon 14 skipping
METex14 skipping
Required: MET amplification
MET amplification
Required: MET fusion
MET fusion
Required: MET activating mutation
MET activating mutation
Performance status
WHO 0–1
Prior therapy
Cannot have received: MET inhibitor
Exception: unless genetic profile demonstrates a mechanism of resistance known to be potentially sensitive to capmatinib
Prior treatment with a selective MET inhibitor or HGF-targeting therapy unless genetic profile demonstrates a mechanism of resistance known to be potentially sensitive to capmatinib
Cannot have received: HGF-targeting therapy
Exception: unless genetic profile demonstrates a mechanism of resistance known to be potentially sensitive to capmatinib
Prior treatment with a selective MET inhibitor or HGF-targeting therapy unless genetic profile demonstrates a mechanism of resistance known to be potentially sensitive to capmatinib
Lab requirements
Blood counts
Adequate organ function as per haematological and biochemical indices within the ranges defined in the protocol.
Kidney function
Adequate organ function as per haematological and biochemical indices within the ranges defined in the protocol.
Liver function
Adequate organ function as per haematological and biochemical indices within the ranges defined in the protocol.
Cardiac function
No clinically significant, uncontrolled heart disease such as unstable angina, recent MI, NYHA III-IV CHF, uncontrolled hypertension, or recent cerebrovascular event.
Adequate organ function as per haematological and biochemical indices within the ranges defined in the protocol. Clinically significant, uncontrolled heart disease such as: unstable angina within three months prior to screening, myocardial infarction within three months prior to screening, history of documented congestive heart failure (NYHA III-IV), uncontrolled hypertension defined by a systolic blood pressure ≥160 mm Hg and/or diastolic blood pressure ≥100 mm Hg, with or without antihypertensive medication. Patients with a cerebrovascular event (including stroke or TIA) within three months before screening.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify